Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | SVP Finance & CFO | March 06, 2023 | March 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date March 06, 2023 · Filed March 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 87,346 |
Reported balance
After 2023-03-06 transaction · row 1
1 source rowRow 1 · 2023-03-06 · Grant · Acquired 30,000 · Balance 87,346 F1: Award comprised of Restricted Stock Units that will vest over 3-years, with 40% vesting on the 1-year anniversary of the date of grant, an additional 40% vesting on the 2-year anniversary of the date of grant, and the remaining 20% vesting on the 3-year anniversary of the date of grant. |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.13 · Expires 2033-03-06 | Direct | 2,555 |
Reported balance
After 2023-03-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-06 · Grant · Acquired 2,555 · Balance 2,555 F2: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 6, 2023, with the final installment vesting on April 6, 2027. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.13 · Expires 2033-03-06 | Direct | 47,445 |
Reported balance
After 2023-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-06 · Grant · Acquired 47,445 · Balance 47,445 F2: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 6, 2023, with the final installment vesting on April 6, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Award comprised of Restricted Stock Units that will vest over 3-years, with 40% vesting on the 1-year anniversary of the date of grant, an additional 40% vesting on the 2-year anniversary of the date of grant, and the remaining 20% vesting on the 3-year anniversary of the date of grant.
F2: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 6, 2023, with the final installment vesting on April 6, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2020 Filed Mar 9, 2020 20:32 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000061 · edgardoc.xml · nonDerivative · entry 1 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,165 F1 · balance_after: Includes up to 513 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 2,767 | $13.94 | $38,571.98 |
DisclosureSEC source: 0001061983-20-000043 · edgardoc.xml · nonDerivative · entry 1 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,165 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/27/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 513 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 20:39 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 4,399 | $14.07 | $61,871.94 |
DisclosureSEC source: 0001061983-20-000037 · edgardoc.xml · nonDerivative · entry 1 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,932 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/26/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 513 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 26, 2019 Filed Mar 4, 2019 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 35,732 | $7.14 Strike: $7.14 | $255,126.48 |
DisclosureSEC source: 0001061983-19-000023 · edgardoc.xml · derivative · entry 3 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,732 Underlying: Common Stock · 35,732 shares Expires 2029-02-26 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| February 26, 2019 Filed Mar 4, 2019 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 14,268 | $7.14 Strike: $7.14 | $101,873.52 |
DisclosureSEC source: 0001061983-19-000023 · edgardoc.xml · derivative · entry 2 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,268 Underlying: Common Stock · 14,268 shares Expires 2029-02-26 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| February 26, 2019 Filed Mar 4, 2019 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-19-000023 · edgardoc.xml · nonDerivative · entry 1 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · deemedExecutionDate: This award shall vest over three years in annual installments: 40% one year from the date of grant, 40% two years from the date of grant and 20% three years from the date of grant. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 38,333 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-18-000015 · edgardoc.xml · derivative · entry 3 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,333 Underlying: Common Stock · 38,333 shares Expires 2028-02-27 F2 · derivative.exercise_date: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-18-000015 · edgardoc.xml · derivative · entry 2 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 1,667 shares Expires 2028-02-27 F2 · derivative.exercise_date: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 20,000 | $0.00 | $20.00 |
DisclosureSEC source: 0001061983-18-000015 · edgardoc.xml · nonDerivative · entry 1 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/27/2019, 40% on 02/27/2020 and 20% on 03/01/2021. Read SEC document |
| June 30, 2017 Filed Jun 30, 2017 23:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 41,944 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000041 · edgardoc.xml · derivative · entry 2 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,944 Underlying: Common Stock · 41,944 shares Expires 2027-06-30 F1 · derivative.exercise_date: When the ISO and NQ dated 06/30/17 are combined for a total grant of 75,000 shares, the option shall vest and become exercisable as to 18,750 shares on 06/30/18 and the balance of 56,250 divided into equal monthly installments thereafter such that the option shall be 100% vested on 06/30/21. Read SEC document |
| June 30, 2017 Filed Jun 30, 2017 23:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 33,056 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000041 · edgardoc.xml · derivative · entry 1 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,056 Underlying: Common Stock · 33,056 shares Expires 2027-06-30 F1 · derivative.exercise_date: When the ISO and NQ dated 06/30/17 are combined for a total grant of 75,000 shares, the option shall vest and become exercisable as to 18,750 shares on 06/30/18 and the balance of 56,250 divided into equal monthly installments thereafter such that the option shall be 100% vested on 06/30/21. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.